Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4951013 - Rimegepant for prevention of chronic migraine in adolescents
2023-505601-16-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Rimegepant arm with Placebo arm (2 arms). Primary endpoint: Mean change in migraine days per month. Planned start Oct 2024; status: authorised.
02
Drugs
rimegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2023-505601-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505601-16-00.